Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous

NCT05510713 | Unknown DMC

• 1 other identifier: jv-fv-RRT
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Acute kidney failure (AKI) is one of the most important causes of morbidity and mortality for critical ill patients. The use of blood purification treatment such as renal replacement therapy (CRRT) and plasma exchange has gradually developed into an effective treatment. However, the efficiency of blood purification may be affected by the recirculation of dual-lumen venous catheter for some special patients including patients with vena cava reflux disorder from massive occupations or ascites. For extreme cases like patients with vena cava disconnection or severe obstruction, the traditional blood purification treatment cannot work effectively. Thus, we used the dual-cannula in jugular-femoral venous blood purification therapy in the following two patients and found that it can improve the perfusion of systemic circulation and the prognosis of patients

Conditions

Blood Purification; Dual-cannula; Vena Cava Disconnection

Outcome Measures

Primary Outcomes (2)

• vasoactive drugs

  doses of vasoactive drugs

  144 hours after dual-cannula in jugular-femoral venous

• ICU mortality

  Measurement of ICU mortality

  28-day ICU mortality

Secondary Outcomes (1)

• Cytokine

  24hous after dual-cannula in jugular-femoral venous

Study Arms (2)

the treatment-as-usual group

NO INTERVENTION

we used the single-cannula in femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction

intervention group

EXPERIMENTAL

we used the dual-cannula in jugular-femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction

Device: Hemodialysis Catheter

Interventions

Hemodialysis Catheter DEVICE

We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous

intervention group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.)
• \. presence of superior vena cava and/or inferior vena cava reflux disorders
• \. age greater than 18 years

You may not qualify if:

• \. Inability to establish suitable vascular access
• \. Pregnant women
• \. Not agreeing to active life support treatment
• \. Severe active bleeding

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

Study Officials

• Minjie Ju, PHD

  Shanghai Zhongshan Hospital

  STUDY DIRECTOR

Central Study Contacts

Zhunyong Gu

CONTACT

8613918677995; gu.zhunyong@zs-hospital.sh.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 18, 2022
• First Posted: August 22, 2022
• Study Start: September 1, 2022
• Primary Completion: September 1, 2024
• Study Completion: October 1, 2024
• Last Updated: August 22, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share